Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome

  title={Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome},
  author={Lingyun Wu and Xiao Li and Ji-ying Su and Chun-kang Chang and Qi He and Xi Zhang and Li Xu and Lu-xi Song and Quan Pu},
  journal={Leukemia \& Lymphoma},
  pages={1461 - 1467}
A total of 32 patients (25 with advanced MDS and 7 with t-AML) were enrolled in this study to evaluate the efficacy and toxicity of the low-dose cytarabine and homoharringtonine in combination with granulocyte colony-stimulating factor (G-CSF) (CHG protocol) in patients with advanced myelodysplastic syndromes (MDS) or MDS-transformed acute myeloid leukemia (t-AML). All the patients were administered the CHG regimen comprising low-dose cytarabine (25 mg/day, intravenous continuous infusion, days… 

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia

The CAG regimen might be an alternative to conventional chemotherapy in older patients with AML in these patients who have had previous myelodysplastic syndrome.

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

The CHG priming regimen provided a safe and effective salvage regimen for higher risk MDS patients who were resistant to decitabine and was endurable for most of the patients.

HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants

The HAG regimen is an effective and safe regimen for the treatment of AML and MDS, and appears to be more effective and better tolerated than intensive chemotherapy.

Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study

Both decitabine and CHG regimen are effective for higher risk MDS; there is no cross resistance between the regimens.

(AraC) and aclarubicin combination therapy as induction treatment for myelodysplastic syndromes-refractory anemia

HAA combination therapy is a suitable induction regimen for patients with MDS-RAEB, which may improve the outcome for de novo higher-risk MDS patients, particularly of those with favorable and intermediate cytogenetics.

High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China

High-dose homoharringtonine as a first-line regimen prolonged overall survival with minimal toxicity in the subset of elderly patients with acute monocytic leukemia, but does not clearly increase the complete remission rate of elderly Patients with acute myeloid leukemia.

Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study

The new priming regimens improved the RR, lowered the recurrence rate, and improved survival in AML and middle-and-high-risk MDS, without significantly increasing adverse events.

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia

Interestingly, it was observed that the CLAG-based regimen did not affect CR, while it achieved a numerically higher ORR rates and significant favorable OS, and should be a prioritized treatment option for R/R AML patients.

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis

HHT and Bortezomib synergistically inhibit SKM-1 cell proliferation and induce apoptosis in vitro and miR-3151 abundance is implicated in SKM -1 cell viability,cell proliferation and p53 protein expression.



Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: A Multicenter Study of 112 Chinese Patients

The CAG regimen seems promising, with acceptable toxicity, for the treatment of various categories of poor-prognosis AML and MDS-RAEBt and nonhematologic toxicities were not observed in this study.

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia wit

CAG as the induction therapy seems promising for the treatment of various categories of poor-prognosis AML.

Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.

Although this is a preliminary study, the CAG combination seems promising for the treatment of relapsed AML, with its low toxicity contributing to a higher quality of life for the patient.

Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Sensation of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML and does not improve the outcome in the subgroup with an unfavorable prognosis.

Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.

Administration of HHT at a lower dose or in combination with hematopoietic growth factors may lead to better results, but treatment with HHT as single agent at this dose and schedule is not currently recommended for patients with MDS and MDS evolving to AML.

Phase II study of low‐dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

It is concluded that homoharringtonine, at the dose schedule investigated, has definite but low antileukemic efficacy and the role of such therapy in myeloproliferative disorders, especially chronic myelogenous leukemia, deserves consideration.

Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.

The dose of HHT 4 mg/m2 for 7 days by continuous infusion in combination with cytarabine is safe for patients with AML; and this combination is appropriate for a phase II evaluation.

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

It is concluded that addition of ATRA +/- G-CSF to FAI had no effect on CR rate, survival, EFS, or EFS in CR in poor prognosis, newly diagnosed AML or high-risk MDS.